We read with great interest the paper by Giovanni Ceresoli and colleagues on the STELLAR study, a single-arm phase 2 study investigating Tumour Treating Fields (TTFields) in addition to standard first-line chemotherapy (platinum–pemetrexed) in malignant pleural mesothelioma. This new and innovative approach in malignant pleural mesothelioma has received US Food and Drug Administration approval under the Humanitarian Device Exemption pathway. However, in our opinion a few points require consideration before implementation of this strategy into daily practice.

中文翻译：

---

间皮瘤的肿瘤治疗领域。

我们非常感兴趣地阅读了Giovanni Ceresoli及其同事关于STELLAR研究的论文，该研究是一项单臂2期研究，研究了除恶性胸膜间皮瘤的标准一线化疗（铂培美曲塞）外的肿瘤治疗领域（TTFields）。这种针对恶性胸膜间皮瘤的创新方法已获得美国食品和药物管理局（US Food and Drug Administration）批准的“人道器械豁免”途径。但是，我们认为，在将该策略实施到日常实践之前，需要考虑几点。